Physician profile
Daniel C Fechtner
NPI 1467440487
$1,948.00
in general payments reported to CMS, 2019-2025
15 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $79.02 · 2021: $237 · 2022: $316 · 2023: $586 · 2024: $380 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $804.71 | 2022-2025 | |
| Allergan, INC. | $300.76 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $255.58 | 2019-2022 | |
| Piramal Critical Care | $218.44 | 2019-2025 | |
| Amgen INC. | $74.20 | 2022-2024 | Prolia, Evenity |
| Vertex Pharmaceuticals Incorporated | $50.82 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $40.16 | 2023 | Xeomin |
| Medtronic, INC. | $36.60 | 2021-2024 | Synchromedii |
| Abbott Laboratories | $32.28 | 2025 | Proclaim |
| Ibsa Pharma INC. | $31.32 | 2023 | Tirosint, Licart |
| Otsuka America Pharmaceutical, INC. | $31.13 | 2023 | Nuedexta |
| Biogen, INC. | $22.34 | 2024 | Skyclarys |
| Dentsply Ih Ab | $20.53 | 2024 | Navina Rectal Catheter Set Regular |
| Avanir Pharmaceuticals, INC. | $15.14 | 2022 | |
| Coloplast Corp | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fechtner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.